Cornea

Study investigators found that the injuries ranged from deep thermal burns to full-thickness corneal or scleral lacerations, with one case of traumatic cataract.

Specular microscopy showed that the ocular symptoms in the patients who had had COVID-19 included conjunctival hyperemia, foreign body sensation, tearing, ocular secretion, and chemosis.

Kefla G. Brown, OD, MS, overviewed her NOA Convention talk on identifying both common and uncommon etiologies of pediatric uveitis.

Study investigators conducted a case-control study to investigate the corneal topography parameters and biomechanics in patients with alopecia areata.

The primary endpoint will be pain improvement as measured by visual analogue scale (VAS) compared to placebo.

What to know about evolving guidelines and potential medicolegal risks.

The study also discovered a need for more blatant labeling on e-liquid containers to help reduce accidental contact with the ocular surface.

The company plans to finalize its Phase 3 development plans following an End-of-Phase 2 meeting with the FDA.

The study demonstrated sustained safety and efficacy of cyclosporine ophthalmic solution (Vevye) 0.1%, with many patients now entering their sixth refill cycle, according to the company.

The pachymeter is the most lightweight handheld product of its kind on the market, according to the company.

Investigators found more cases than expected following tomography of 2007 eyes.

Barry Eiden, OD, FAAO, FSLS, President and Co-founder of IKA, talked about his session at the meeting centering around the pediatric prevalence of keratoconus, the importance of early diagnosis, and the impact this can have on practices.

Alan Glazier, OD, FAAO, talked about moderating a session discussing the education of the public on keratoconus, from screening to diagnosis, and the roles clinicians can take to assist in the patients' anxieties.

Andrew Morgenstern, OD, FAAO, FNAP, President and Co-founder of IKA, talked about his session at the meeting that discussed the prevalence of keratoconus in the pediatric population in the US.

The 2 FDA registration trials for perfluorohexyloctane resulted in scientifically significant results for improvement of mild and moderate symptoms of dry eye disease.

The collective enhances education, research, and quality of life.

Controversies in Modern Eye Care cochair Arjan Hura, MD, details new expansions to the conference's schedule, which include discussions on retina gene therapies, corneal endothelial diseases, and oculoplastics.

The IOL launch is the company’s second market debut in less than 12 months.

What axial length readings and crystalline lens power tell you.

Pterygium is an ocular disease commonly referred to as “surfer’s eye,” which can result from exposure to high levels of UV radiation.

Before the ASCRS 2024 meeting, TheiaNova CEO Carissa Fonseca, PhD, pitched a novel keratoconus treatment.

The study authors also noted that patients responding well to routine intense pulsed light sessions do not need to undergo additional sessions.

The 1-time, intracameral injection is a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction.

Shifting the treatment paradigm can lead to less pain, inflammation

Dr Brianna Rhue, OD, FAAO, FSLS details her upcoming presentation "Cutting Out Surgery for the Management of Refractive Error," where she will detail the underutilization of orthokeratology during Vision Expo East 2024 later this week.

Ferroptosis is a form of cell death that depends on the presence of iron in the cells.

Barry Eiden, OD, FAAO, FSLS, sits down with Optometry Times to highlight the importance of staying up-to-date with technology in the development of treatment and diagnosis of keratoconus and what's to come at this year's IKA Keratoconus Symposium in May.

Oluwatosin U Smith, MD, urges consideration of the interaction between corneal and glaucomatous disease whenever treating glaucoma or corneal issues during the annual Glaucoma 360 meeting in San Francisco, California.

OKYO Pharma announced the acceptance of OK-101 as an investigational new drug following clinical studies investigating the candidate in patients with neuropathic corneal pain, the first to do so.

The study, based out of India, successfully transplanted 32 of 34 corneas harvested from drowning victims.